168 related articles for article (PubMed ID: 36215227)
41. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
[TBL] [Abstract][Full Text] [Related]
42. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Biswas M; Chatterjee SS; Boila LD; Chakraborty S; Banerjee D; Sengupta A
FASEB J; 2019 Apr; 33(4):5268-5286. PubMed ID: 30668141
[TBL] [Abstract][Full Text] [Related]
43. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Yi J; Shi X; Xuan Z; Wu J
Cancer Lett; 2021 Feb; 499():188-200. PubMed ID: 33253789
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
Lu H; Xie Y; Tran L; Lan J; Yang Y; Murugan NL; Wang R; Wang YJ; Semenza GL
J Clin Invest; 2020 Sep; 130(9):4607-4623. PubMed ID: 32427586
[TBL] [Abstract][Full Text] [Related]
45. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.
Li X; Zhang Q; Shi Q; Liu Y; Zhao K; Shen Q; Shi Y; Liu X; Wang C; Li N; Ma Y; Cao X
J Autoimmun; 2017 Jun; 80():85-94. PubMed ID: 28284523
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA‑3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.
Shou T; Yang H; Lv J; Liu D; Sun X
Mol Med Rep; 2019 Feb; 19(2):1049-1055. PubMed ID: 30483744
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of histone lysine demethylase 6A promotes chondrocytic activity and attenuates osteoarthritis development through repressing H3K27me3 enhancement of Wnt10a.
Lian WS; Wu RW; Ko JY; Chen YS; Wang SY; Jahr H; Wang FS
Int J Biochem Cell Biol; 2023 May; 158():106394. PubMed ID: 36871937
[TBL] [Abstract][Full Text] [Related]
48. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy.
Chen LJ; Xu XY; Zhong XD; Liu YJ; Zhu MH; Tao F; Li CY; She QS; Yang GJ; Chen J
Bioorg Chem; 2023 Apr; 133():106409. PubMed ID: 36753963
[TBL] [Abstract][Full Text] [Related]
49. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
Wolf A; Agnihotri S; Micallef J; Mukherjee J; Sabha N; Cairns R; Hawkins C; Guha A
J Exp Med; 2011 Feb; 208(2):313-26. PubMed ID: 21242296
[TBL] [Abstract][Full Text] [Related]
50. Large Intergenic Non-coding RNA-RoR Inhibits Aerobic Glycolysis of Glioblastoma Cells
Li Y; He ZC; Liu Q; Zhou K; Shi Y; Yao XH; Zhang X; Kung HF; Ping YF; Bian XW
J Cancer; 2018; 9(5):880-889. PubMed ID: 29581766
[TBL] [Abstract][Full Text] [Related]
51. The EP300, KDM5A, KDM6A and KDM6B chromatin regulators cooperate with KLF4 in the transcriptional activation of POU5F1.
Wang WP; Tzeng TY; Wang JY; Lee DC; Lin YH; Wu PC; Chen YP; Chiu IM; Chi YH
PLoS One; 2012; 7(12):e52556. PubMed ID: 23272250
[TBL] [Abstract][Full Text] [Related]
52. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism.
Liao Y; Luo Z; Lin Y; Chen H; Chen T; Xu L; Orgurek S; Berry K; Dzieciatkowska M; Reisz JA; D'Alessandro A; Zhou W; Lu QR
Cell Death Dis; 2022 Nov; 13(11):943. PubMed ID: 36351894
[TBL] [Abstract][Full Text] [Related]
53. The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Schulz WA; Lang A; Koch J; Greife A
Int J Cancer; 2019 Aug; 145(3):614-620. PubMed ID: 30628063
[TBL] [Abstract][Full Text] [Related]
54. Histone Demethylase KDM6A Controls the Mammary Luminal Lineage through Enzyme-Independent Mechanisms.
Yoo KH; Oh S; Kang K; Wang C; Robinson GW; Ge K; Hennighausen L
Mol Cell Biol; 2016 Aug; 36(16):2108-20. PubMed ID: 27215382
[TBL] [Abstract][Full Text] [Related]
55. CircCDKN2B-AS1 interacts with IMP3 to stabilize hexokinase 2 mRNA and facilitate cervical squamous cell carcinoma aerobic glycolysis progression.
Zhang Y; Zhao L; Yang S; Cen Y; Zhu T; Wang L; Xia L; Liu Y; Zou J; Xu J; Li Y; Cheng X; Lu W; Wang X; Xie X
J Exp Clin Cancer Res; 2020 Dec; 39(1):281. PubMed ID: 33308298
[TBL] [Abstract][Full Text] [Related]
56. Catalytic domain-dependent and -independent transcriptional activities of the tumour suppressor histone H3K27 demethylase UTX/KDM6A in specific cancer types.
Sun W; Lee KL; Poellinger L; Masai H; Kato H
Epigenetics; 2023 Dec; 18(1):2222245. PubMed ID: 37300822
[TBL] [Abstract][Full Text] [Related]
57. Significance of KDM6A mutation in bladder cancer immune escape.
Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
[TBL] [Abstract][Full Text] [Related]
58. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
59. MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma.
Alfardus H; McIntyre A; Smith S
Biomed Res Int; 2017; 2017():9157370. PubMed ID: 28804724
[TBL] [Abstract][Full Text] [Related]
60. mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.
Zhang H; Su X; Burley SK; Zheng XFS
Theranostics; 2022; 12(7):3518-3533. PubMed ID: 35547764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
